Evofem Biosciences Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • EVFM

Stock Symbol

  • Investments
  • 2

Evofem Biosciences General Information

Description

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

Contact Information

Website
www.evofem.com
Formerly Known As
Instead Healthcare
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 12636 High Bluff Drive
  • Suite 400
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Personal Products
Stock Exchange
OTCM
Corporate Office
  • 12636 High Bluff Drive
  • Suite 400
  • San Diego, CA 92130
  • United States
+1 (858)

Evofem Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evofem Biosciences Stock Performance

As of 13-Nov-2026, Evofem Biosciences’s current market cap is $822K with 133M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$822K 133M 152K -$0.11

Evofem Biosciences Financials Summary

As of 30-Jun-2026, Evofem Biosciences has a trailing 12-month revenue of $18M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 56,940 58,247 50,329 43,717
Revenue 18,045 20,183 19,363 18,218
EBITDA (14,912) 1,004 (8,120) 54,746
Net Income (15,282) 391 (8,860) 52,979
Total Assets 7,522 20,274 23,789 10,554
Total Debt 55,031 54,548 45,967 43,373
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Evofem Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Evofem Biosciences‘s full profile, request access.

Request a free trial

Evofem Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Evofem Biosciences‘s full profile, request access.

Request a free trial

Evofem Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing produ
Pharmaceuticals
San Diego, CA
29 As of 2026

Lexington, MA
 

Ingelheim Am Rhein, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evofem Biosciences Competitors (34)

One of Evofem Biosciences’s 34 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Boehringer Ingelheim Corporation Ingelheim Am Rhein, Germany
Daré Bioscience Formerly VC-backed San Diego, CA
Agile Therapeutics Formerly VC-backed Princeton, NJ
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 34 competitors. Get the full list »

Evofem Biosciences Patents

Evofem Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12280037-B2 Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof Active 22-Sep-2020
US-20220087978-A1 Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof Active 22-Sep-2020
US-20260007637-A1 Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof Pending 22-Sep-2020
US-12172969-B2 Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof Active 05-Sep-2018
US-20200071279-A1 Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof Inactive 05-Sep-2018 A61K31/4164
To view Evofem Biosciences’s complete patent history, request access »

Evofem Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evofem Biosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Evofem Biosciences‘s full profile, request access.

Request a free trial

Evofem Biosciences Acquisitions (2)

Evofem Biosciences’s most recent deal was a Merger/Acquisition with Lupin (U.S. Commercial Women's Health Specialty Business and SOLOSEC) for . The deal was made on 15-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lupin (U.S. Commercial Women's Health Specialty Business and SOLOSEC) 15-Jul-2024 Merger/Acquisition Other Healthcare Services
Evofem Biosciences (Pharmaceuticals) 17-Jan-2018 Merger/Acquisition Pharmaceuticals
To view Evofem Biosciences’s complete acquisitions history, request access »

Evofem Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Evofem Biosciences’s complete esg history, request access »

Evofem Biosciences FAQs

  • When was Evofem Biosciences founded?

    Evofem Biosciences was founded in 2007.

  • Where is Evofem Biosciences headquartered?

    Evofem Biosciences is headquartered in San Diego, CA.

  • What is the size of Evofem Biosciences?

    Evofem Biosciences has 29 total employees.

  • What industry is Evofem Biosciences in?

    Evofem Biosciences’s primary industry is Pharmaceuticals.

  • Is Evofem Biosciences a private or public company?

    Evofem Biosciences is a Public company.

  • What is Evofem Biosciences’s stock symbol?

    The ticker symbol for Evofem Biosciences is EVFM.

  • What is the current market cap of Evofem Biosciences?

    The current market capitalization of Evofem Biosciences is $822K.

  • What is Evofem Biosciences’s current revenue?

    The trailing twelve month revenue for Evofem Biosciences is $18M.

  • Who are Evofem Biosciences’s competitors?

    Dicerna Pharmaceuticals, Boehringer Ingelheim, Daré Bioscience, Agile Therapeutics, and Merck & Co. are some of the 34 competitors of Evofem Biosciences.

  • What is Evofem Biosciences’s annual earnings per share (EPS)?

    Evofem Biosciences’s EPS for 12 months was -$0.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process